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Summary
 
Complement receptor 1–related gene/protein y (Crry) is a potent murine membrane comple-
ment regulator that inhibits classical and alternative pathway C3 convertases. In nephrotoxic
serum (NTS) nephritis, injected antibodies (Abs) bind to glomeruli, leading to complement ac-
tivation and subsequent glomerular injury and albuminuria. To study the phenotypic effects of
continuous complement pathway blockade, transgenic mice were created that express recom-
binant soluble (rs) Crry directed by the broadly active and heavy metal-inducible metallothio-
nein-I promoter. One transgenic line expressing high levels of rsCrry was propagated. Serum
rsCrry levels were 18.7 
 
6
 
 2.7 
 
m
 
g/ml (
 
n
 
 5 
 
5) at basal level and increased to 118.1 
 
6
 
 20.6 
 
m
 
g/ml
4 d after addition of zinc to the drinking water. By reverse transcription polymerase chain reac-
tion (RT-PCR), transgene messenger (m)RNA was present in liver, kidney, brain, lung, and
spleen, but not in heart. By in situ RT-PCR analysis of kidneys, transgene mRNA was widely
expressed both in renal glomeruli and tubules. Urinary excretion of rsCrry was 113.4 
 
6
 
 22.4
 
m
 
g/ml with a fractional excretion relative to creatinine of 13.2 
 
6
 
 2.7%, consistent with local
renal production of rsCrry and secretion into urine. The founder and all transgene positive
adult animals have remained healthy with no mortality or apparent phenotypic abnormalities,
including infection or immune complex disease. To determine whether rsCrry blocked comple-
ment-mediated injury, NTS nephritis was induced by injection of NTS immunoglobulin
(Ig)G, followed by an 18-h urine collection to quantitate the excretion of albumin as a measure
of glomerular injury. In transgene-negative littermates (
 
n
 
 5 
 
15), transgene-positive animals (
 
n
 
 5
 
10), and transgene-positive animals fed zinc (
 
n
 
 5 
 
10), albuminuria was 4,393 
 
6
 
 948, 1,783 
 
6
 
454, and 1,057 
 
6
 
 277 
 
m
 
g/mg creatinine, respectively (
 
P
 
 
 
, 
 
0.01 by ANOVA). Glomerular C3
was evident by immunofluorescence staining in 12/15 transgene-negative animals, but in none
of the transgene-positive animals fed zinc. Thus, we have produced the first transgenic animals
that overexpress a soluble C3 convertase inhibitor. rsCrry expression markedly ameliorates an
Ab-induced disease model in vivo. These results support the hypothesis that continuous com-
plement inhibition at the C3 convertase step is feasible and effective in complement-mediated
injury states.
Key words: Crry • mice, transgenic • anti-glomerular basement membrane disease • 
complement inactivators • complement
 
A
 
ctivation of the complement pathway occurs after the
binding of Ab to local tissue Ags. Products of comple-
ment activation can lead to varied inflammatory events,
such as recruitment and activation of leukocytes by C3 and
C5 cleavage fragments, as well as a number of cellular
events mediated by C5b-9 (for reviews see references 1, 2).
Using several experimental approaches, the complement
system has been shown to play an important role in im-
mune complex disease models. In early studies, this was
done through systemic depletion of complement with co-
bra venom factor (3). More recently, an mAb that blocks
the cleavage of C5, as well as neutralizing polyclonal Ab to
C5a, has been used successfully (4–6). Rodents that are
congenitally deficient in a single component such as C5 or
C6, or that have been made deficient in a single compo-
nent by homologous recombination, such as C3 or C4 (7),
have also been studied. In these animals with complement
deficiencies, complement activation is blocked distal to the
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absent component, and tissue damage is ameliorated in sev-
eral models of Ab-induced and immune complex diseases
(8–10).
A further means of inhibiting complement has been to
produce intrinsic complement regulators, normally found
as membrane proteins, as recombinant soluble (rs)
 
1
 
 pro-
teins. The most widely studied is human rsCR1, which has
been used successfully in a variety of immune complex dis-
eases, as well as in diseases not traditionally considered to
have an immunological basis, such as myocardial infarction
and ischemia/reperfusion injury (11, 12). In rodents, the
protein Crry (complement receptor 1–related gene/protein
y) functions as a CR1 functional homologue and manifests
that same spectrum of inhibitory activities for both the clas-
sical and alternative pathways (13). The use of Crry as a re-
combinant inhibitor in homologous disease models has the
advantage that an immune response is not expected to oc-
cur, which has limited the use of heterologous proteins
such as rsCR1 to short-term disease models. We have pro-
duced mouse Crry as a recombinant protein bearing a
mouse IgG1 tail (rsCrry-Ig; reference 14) and have shown
that as predicted, it can be chronically administered with-
out adverse effects or the generation of a neutralizing Ab
response (Kraus, D., and V.M. Holers, unpublished data).
The nephrotoxic serum (NTS) nephritis model has been
widely used in several species to illustrate pathogenic events
in glomerular inflammation. The complement dependence
of this disorder in rats was shown years ago (3, 15). In mice
and rabbits, a relative dose dependence is clear, such that
when low doses of Ab are used, the complement depen-
dence of this model is apparent, but becomes lost as higher
Ab doses are used (16, 17), perhaps because of direct effects
of Ab alone (18). Recently, we have successfully used
rsCrry-Ig to inhibit NTS nephritis in mice to the same ex-
tent as seen with complement depletion using cobra venom
factor (14).
In these studies, we tested the hypothesis that mice could
be continuously exposed to therapeutically active levels of a
complement inhibitor both systemically and locally with-
out untoward effects. To accomplish this, we produced
transgenic mice that express rsCrry directed by the metal-
lothionein (MT)-I promoter (19). This promoter, although
primarily active in the liver, can direct mRNA synthesis in
a heavy metal-inducible fashion in many tissues (20).
Hence, we found that Crry is expressed by many cell types
including those of the glomerulus. Crry transgenic mice
have circulating rsCrry levels that lead to continuous com-
plement inhibition in sera. No evidence of spontaneous
clinical complications is apparent in adult transgenic mice,
yet they are markedly protected from renal injury in the
NTS nephritis model.
 
Materials and Methods
 
Construction of MT-Crry–encoding Plasmid.
 
The cDNA encod-
ing soluble mouse Crry (21) was subcloned into the NruI site of
the MT expression vector 2999B4 (gift of Dr. Richard Palmiter,
University of Washington). This vector contains the mouse
MT-I promoter, the human growth hormone polyadenylation
sequence, and the mouse MT gene 5
 
9
 
 and 3
 
9
 
 flanking regions,
which serve as locus control regions to confer position-indepen-
dent and copy number–dependent expression to the transgene (22).
The capacity of the MT-Crry construct to direct production of
rsCrry was determined by stable transfection of BSC-1 cells (pro-
vided by Dr. Gary Toback, The University of Chicago; reference
23). The MT-Crry plasmid was cotransfected with pWLNeo
(Stratagene, La Jolla, CA) by the CaPO
 
4
 
 precipitation method.
Stable transfectants were selected by growth in 400 
 
m
 
g/ml G418.
After overnight incubation in DMEM/10% FCS with or without
80 
 
m
 
M ZnSO
 
4
 
, the culture medium was harvested for Crry
ELISA.
 
Production of Crry Transgenic Mice
 
The pBluescript portion of
the vector was removed by SalI digestion. The 19.4-kb MT-Crry
DNA fragment was gel purified and microinjected into the pro-
nuclei of 1-cell fertilized CD-1 oocytes, and transgenic mice
were generated using standard techniques (24). Screening for
founders was performed on tail-derived DNA using a PCR strat-
egy designed to specifically detect transgenic 
 
Crry
 
, but not endog-
enous 
 
Crry
 
. The 5
 
9
 
 and 3
 
9
 
 primers were 5
 
9
 
-TCG TCC TAT
CCG AGC CAG TCG T-3
 
9
 
 and 5
 
9
 
-GGC AGA AGG AAG
CTG TGA TGG-3
 
9
 
, which hybridize to the MT-I promoter and
 
Crry
 
, respectively. PCR products were also digested with BamHI
or EcoRI. To confirm PCR results, Southern blotting was also
performed on SmaI- or BamHI-digested DNA. As a probe, the
650-bp human growth hormone polyadenylation site was cut
from the MT-Crry construct with EcoRI and BamHI, gel puri-
fied, and 
 
32
 
P labeled.
The 
 
Crry
 
 transgene was propagated by breeding into normal
CD-1 mice (Harlan Sprague Dawley, Inc., Indianapolis, IN).
Offspring were followed for the transgene by PCR as described
above. Because normal mice do not have circulating Crry, confir-
mation of the presence of the functional transgene came from
identifying rsCrry in sera by ELISA. All animal work was ap-
proved and performed under the guidelines set by the University
of Chicago and University of Colorado Institutional Animal Care
and Use Committees.
 
ELISA for Determination of Crry Levels.
 
Dynatech Immulon II
(Dynatech, Chantilly, VA) 96-well plates were coated at 4
 
8
 
C
overnight with 1 
 
m
 
g/well of
 
 
 
IgG purified from rabbit anti–mouse
Crry polyclonal Ab (25). Plates were then washed four times with
PBS, 0.05% Tween 20 (Sigma Chemical Co., St. Louis, MO) and
blocked for 1 h at room temperature with PBS and 1% BSA
(Sigma Chemical Co.). The plates were washed four more times
and then samples diluted in PBS and 0.1% BSA were added for a
1 h incubation. Plates were then decanted and washed four times
before the addition of pretitrated anti-Crry mAb 10A2 coupled
with biotin (
 
N
 
-hydroxy succinimidobiotin; Sigma Chemical Co.)
in PBS, 0.1% BSA. After a 1-h incubation, the plates were again
washed four times. Streptavidin horseradish peroxidase (Sigma
Chemical Co.) diluted in PBS was then added for 30 min. After
four washes, ABTS (Boehringer Mannheim Corp., Indianapolis,
IN) activated with H
 
2
 
O
 
2
 
 was added. Plates were developed in the
dark and the OD
 
480
 
 was measured with a Titertek Plus ELISA
plate reader (ICN Biomedicals, Costa Mesa, CA).
 
Western Blot Analysis.
 
Western blot analysis was performed
using urine dialyzed against PBS. After quantification by ELISA,
 
1
 
Abbreviations used in this paper:
 
 Crry, complement receptor 1–related
gene/protein y; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; IF,
immunofluorescence; MT, metallothionein; NTS, nephrotoxic serum; rs,
recombinant soluble; RT, reverse transcription. 
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urine containing 50 ng rsCrry was analyzed by 12.5% SDS-
PAGE. As a positive control, 50 ng rsCrry-Ig was run in parallel.
After transfer to Hybond-ECL nitrocellulose (Amersham Phar-
macia Biotech Inc., Piscataway, NJ), membranes were incubated
with biotin-conjugated primary mAbs recognizing either Crry
(10A2), or mouse CR1 (8C12; reference 26) as a control, diluted
in PBS with 10% milk, 1% BSA, and 0.1% Tween 20. After
washing four times, membranes were incubated with streptavidin
horseradish peroxidase. After four additional washes, blots were
developed using the ECL system (Amersham Pharmacia Biotech
Inc.).
 
Reverse Transcription PCR.
 
RNA was isolated from different
tissues using TRIzol reagent (GIBCO BRL, Gaithersburg, MD)
followed by phenol-chloroform extraction. cDNA was produced
from 5 
 
m
 
g total RNA by reverse transcription (RT) using oligo-dT
primers (SuperScript Preamplification System; GIBCO BRL). Sub-
sequent PCR was performed in tubes containing the generated
cDNA, 50 mM KCl, 20 mM Tris-HCl, 2.5 mM MgCl
 
2
 
, 2.5%
DMSO, 100 
 
m
 
M of each deoxynucleotide triphosphate, 0.1 
 
m
 
M
of each primer, and 2.5 U of 
 
Taq
 
 polymerase. 25 cycles of a
1-min denaturation at 94
 
8
 
C, 1-min annealing at 60
 
8
 
C, and 1-min
extension at 72
 
8
 
C were performed. The 5
 
9
 
 primer used in the
PCR was 5
 
9
 
-CCT CAC TTA CTC CGT AGC TCC-3
 
9
 
 which
hybridizes to bases 
 
1
 
33 to 
 
1
 
53 of the MT-I promoter and the 3
 
9
 
primer was 5
 
9
 
-CAG CAC TCG TCC AGG TTG AGT C-3
 
9
 
,
which hybridizes to sequence encoding a portion of the first SCR
of Crry. Control PCR was performed using primers for glyceral-
dehyde-3-phosphate dehydrogenase (G3PDH; reference 7).
 
In Situ RT-PCR.
 
Kidneys from Crry transgenic animals and
paired control transgene negative littermates were snap frozen.
4-
 
m
 
m cryosections were fixed in 4% paraformaldehyde in PBS.
Subsequently, sections were treated for 15 min with proteinase K
(10 
 
m
 
g/ml) followed by an overnight incubation in RNAse-free
DNAse (100 U/ml). RT-PCR was performed on the sections
using the same primers described above for solution PCR in 20 mM
Tris-HCl, and 2 mM magnesium acetate. Digoxigenin-dUTP was
added at 4 
 
m
 
M to the deoxynucleotide triphosphates. RT-PCR was
performed with 2.5 U r
 
Tth
 
 DNA polymerase (Perkin-Elmer Corp.,
Norwalk, CT). Initial RT was performed for 30 min at 60
 
8
 
C fol-
lowed by the PCR consisting of 20 cycles of a 45-s denaturation at
94
 
8
 
C, 15-s annealing at 55
 
8
 
C, and 1-min extension at 60
 
8
 
C. The
amplified sequences were detected with alkaline phosphatase conju-
gated anti-digoxigenin Ab, which was developed with NBT/BCIP
(nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate).
 
Purification of Urinary rsCrry.
 
Five transgene positive animals
were fed 25 mM ZnSO
 
4
 
 in drinking water for 1 wk. Animals
were then housed for 1 wk in metabolic cages for urine collec-
tion. Urine was pooled, dialyzed against PBS, and affinity purified
on an anti-Crry mAb 10A2–Sepharose column using conditions
shown to retain protein activity (14). Specifically, after washing
with PBS, material was eluted with 0.1 M Na
 
2
 
CO
 
3
 
-made 0.5 M
NaCl, pH 11. Fractions were neutralized with 0.1 M Tris, pH
6.8. Fractions containing Crry were pooled, concentrated, dia-
lyzed versus PBS, quantitated by ELISA, and then used in assays
of complement inhibition.
 
Analysis of Complement Inhibition.
 
Measurement of complement
activity was performed using previously published quantitative
flow cytometric methods (21, 28). For this assay, complement
was activated on human K562 cells treated with rabbit anti-K562
polyclonal Ab. Because K562 cells are not lysed by mouse com-
plement, C3 deposition was measured by flow cytometry. The
complement inhibitory activity of purified urinary rsCrry added
to 10% BALB/c serum was measured and compared with a stan-
dard curve generated by adding varying amounts of rsCrry-Ig to
sera. In addition, 10% pooled sera from either transgenic mice or
control nontransgenic littermates were evaluated in this assay.
The negative controls were sera containing 10 mM EDTA, and
the positive control was BALB/c serum with no Crry. Samples
were incubated at 37
 
8
 
C for 20 min in 2 mM MgCl
 
2
 
 and 0.15 mM
CaCl
 
2
 
-containing buffer after which the reaction was stopped
with 10 mM EDTA. K562 cells were then washed twice with
PBS, 1% BSA and incubated with FITC-conjugated goat anti–
mouse C3 (Cappel Laboratories, Malvern, PA) for 1 h on ice. Af-
ter washing with the same buffer and fixation using 1% paraform-
aldehyde, cells were analyzed for the level of C3 binding by flow
cytometry using an EPICS cytometer (Coulter Immunology, Hi-
aleah, FL). Percentage inhibition was calculated using the formula
(1 
 
2 
 
[sample MCF 
 
2 
 
background {10 mM EDTA condition}]/
[positive control MCF {no Crry} 
 
2 
 
background]) 
 
3 
 
100.
 
Induction of NTS Nephritis.
 
NTS raised in a single sheep was
supplied by Dr. David Salant (Boston University Medical Center;
reference 29). The complement-fixing IgG
 
1
 
 subclass was isolated
by anion-exchange chromatography on DEAE-Sephacel (30).
NTS nephritis was induced in 10 transgene positive mice and 15
transgene negative littermates. An additional 10 transgene positive
mice were fed 25 mM ZnSO
 
4
 
 in drinking water before disease
induction. Disease was induced at the same time in the three
groups. An equal number of males and females were studied.
NTS IgG was injected at a dose of 0.5 mg i.v., after which ani-
mals were housed for 18 h in metabolic cages to collect urine.
Mice were then killed to harvest blood and renal tissue. Identical
studies were performed in which mice were injected intrave-
nously with either 1.0 or 2.0 mg NTS IgG. For these, three
transgene positive males and four transgene negative littermate
males were studied at each dose. To examine the transient neu-
trophil influx observed in this model (31), another group of stud-
ies was performed in which three transgene positive males and
four transgene negative males were injected with 0.5 mg i.v.
NTS IgG. Animals were killed 2 h later for tissue harvest.
Urinary albumin concentration was measured by ELISA as
previously described (10), whereas urinary creatinine was mea-
sured with a Beckman Autoanalyzer. To normalize albumin ex-
cretion, data are expressed as 
 
m
 
g albumin/mg creatinine (10, 31).
Normal mice excrete 
 
,
 
25 
 
m
 
g albumin/mg creatinine, similar to
the case in humans. Direct immunofluorescence (IF) microscopy
for sheep IgG and mouse C3 was performed on snap-frozen renal
tissue (32). The number of neutrophils stained with mAb 7/4
(Serotec Ltd., Kidlington, Oxford, UK) in at least 60 glomeruli/
animal was counted (10). Glomerular IF scoring and neutrophil
counts were accumulated in a blinded fashion.
Statistical analyses were performed with Minitab Software
(College Park, PA). Data are expressed as mean 
 
6
 
 SEM. Statisti-
cal significance was determined by one-way analysis of variance
followed by Tukey’s pairwise comparisons, using a family error
rate of 0.05 to indicate statistical significance.
 
Results
 
Production and Characterization of Crry Transgenic Mice.
 
The construct shown in Fig. 1 was created by subcloning
cDNA encoding the signal peptide and extracellular do-
main of mouse Crry, without the transmembrane or intra-
cellular domains, into the expression vector MT-2999B4,
containing the mouse MT-I promoter and 5
 
9
 
/3
 
9
 
 MT gene
flanking sequences. BSC-1 cells were stably transfected 
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with this construct. When cells were grown in medium
alone, there was no detectable rsCrry in the culture me-
dium, but with inclusion of 80 
 
mM ZnSO4 in culture me-
dium, there was 2.21 mg/ml rsCrry after a 12-h culture.
Thus, this construct directs production of rsCrry that is un-
der control of a heavy metal-inducible promoter.
Transgenic mice were generated with the SalI-SalI mi-
croinjection fragment. Transgene positive animals were
identified by PCR (Fig. 2). These PCR products contained
the expected single BamHI and EcoRI cleavage sites.
Southern blot analysis with the 650-bp human growth hor-
mone fragment confirmed the presence of the transgene
(not shown). One founder line was propagated that had de-
sired serum levels and tissue expression of Crry. The Crry
transgene was perpetuated in CD-1 mice and all studies de-
scribed in this report were performed with F2 animals. In
184 F2 animals tested after weaning, 76 were positive for
the transgene (41.3%). This departs from a Mendelian
mode of inheritance (P , 0.02 by chi-square goodness-of-
fit test). The reason for this is unexplained, but several pos-
sibilities exist. rsCrry may partially interfere with fertiliza-
tion or gestation, or lead to an unobserved increased perinatal
or neonatal mortality. These issues were not addressed in
this study. However, after weaning of transgene positive
animals, no phenotypic abnormalities were present, and no
mortality was observed (discussed further below).
Serum rsCrry levels were 18.7 6 2.7 mg/ml (n 5 5) in
the basal state, which increased to 118.1 6 20.6 mg/ml 4 d
after addition of 25 mM ZnSO4 to drinking water. As ex-
pected, none of the transgene negative littermate animals
with or without zinc feeding had detectable serum Crry, as
there is no intrinsic soluble serum Crry. Urinary excretion
of rsCrry was also measured. As with sera, there was no de-
tectable Crry in the urine of Crry transgene negative litter-
mate animals. In contrast, Crry transgene animals had high
urinary levels of rsCrry (111.3 6 22.4 mg/ml; n 5 4). The
fractional excretions of rsCrry and albumin relative to creat-
inine, which is freely filtered at the glomerulus, were 13.2 6
2.7% and 0.00012 6 0.00002%, respectively. Since the size
(45 kD) and charge (pI 5.6) of rsCrry (21) are near those of
albumin, this z100,000-fold difference between the two
supports the conclusion that rsCrry is actively produced in
the kidney.
To further evaluate the expression of the Crry transgene,
RT-PCR was performed. RNA from kidney, liver, spleen,
lung, heart, and brain were isolated. RT-PCR was per-
formed using a 59 primer from the 59 untranslated region of
the MTH promoter construct and a 39 primer from mouse
Crry. This strategy allows PCR amplification of the trans-
gene derived mRNA only. As shown in Fig. 3, after 25 cy-
cles of PCR, Crry mRNA from the tg was present in all
organs but heart. As a control for RNA integrity, RT-
PCR for G3PDH showed equivalent intensities of PCR
product. To verify that RNA was not contaminated with
genomic DNA, controls for each organ were performed in
which RNA was treated identically, except that reverse
transcription was not performed (in Fig. 3, the control for
liver is shown). Thus, the Crry transgene mRNA is present
in many tissues, with liver expression being the most prom-
inent, as predicted (19, 33).
The localization of Crry transgene mRNA in kidney was
evaluated by in situ RT-PCR. mRNA for the transgene
was strongly positive in glomeruli (Fig. 4 A) and tubules
(Fig. 4 B). As also illustrated, kidney from a transgene neg-
ative littermate was negative (Fig. 4 C). These RT-PCR
data showing prominent renal expression are consistent
with the appearance of substantial quantities of rsCrry in
the urine. Furthermore, they show that we have achieved
the desired local production of rsCrry in the glomerulus.
Figure 1. Schematic representation of the plasmid construct used to
generate Crry transgenic mice. cDNA for the signal sequence and five
short consensus repeats (SCR’s) of mouse Crry was subcloned into the
MT 59/39 vector. This vector uses the mouse MT-I promoter, the human
growth hormone polyadenylation site, and the mouse MT gene locus
control regions contained within 59 and 39 hypersensitive sites. The
pBluescript portion of the plasmid was removed by SalI digestion.
Figure 2. Detection of the Crry trans-
gene by PCR. PCR was performed on tail-
derived DNA from the founder and selected
F2 offspring using 59 and 39 primers derived
from the MT-I promoter and Crry, respec-
tively. The arrow indicates the 464-bp PCR
product.
Figure 3. RT-PCR showing the tissue localization of the Crry trans-
gene mRNA. PCR was performed for 25 cycles using a 59 primer de-
rived from the 59 untranslated region of the mRNA derived from the
MTH promoter construct and a 39 primer from mouse Crry sequence. As
a positive control, RT-PCR for G3PDH was performed, and a negative
control included RNA which was treated identically, except that reverse
transcription was not performed. This is demonstrated for liver and desig-
nated 2RT.1325 Quigg et al.
Functional Characterization of rsCrry in Crry Transgenic
Mice. Complement activity in Crry transgenic mice was
evaluated. Five male Crry transgenic and control transgene
negative animals were killed and sera were pooled. The
percent inhibition of C3 deposition on Ab-sensitized K562
cells relative to pooled sera from male transgene negative
littermates was determined. In this assay, complement acti-
vation was inhibited by 71.6% in sera from transgene posi-
tive animals.
To evaluate rsCrry appearing in the urine, five animals
were zinc fed and housed in metabolic cages. Urine was
collected, pooled, dialyzed against PBS, and then subjected
to Western blotting with mAb 10A2. By this approach, a
single 45-kD band was identified (Fig. 5, lane 2). In this
analysis, rsCrry-Ig was included as a positive control for re-
activity with mAb 10A2 (lane 1). As a negative control,
mAb 8C12, specific for mouse CR1, did not react with
urinary proteins from Crry transgenic animals (lane 4), nor
with rsCrry-Ig (lane 3).
rsCrry was purified from dialyzed urine by affinity chro-
matography using mAb 10A2-Sepharose. The activity of
this rsCrry preparation was compared with rsCrry-Ig and
shown to have equivalent complement inhibitory activity
on a molar basis (data not shown). Therefore, as expected
using this Crry cDNA (21) functional rsCrry is produced in
Crry transgenic animals.
Chronic Complement Inhibition in Crry Transgenic Mice Is
Not Detrimental. Given the propensity to develop im-
mune complex disease in humans with complement defi-
ciencies (34) and the demonstrated abnormalities in im-
mune complex handling in complement deficient animals
hyperimmunized with foreign Ag (10), it was important to
exclude spontaneous immune complex disease in Crry
transgenic animals. All Crry transgenic animals identified
after weaning have remained healthy with no mortality in
all mice studied, including the 18-mo-old founder. Urinary
albumin excretion is normal (15.6 6 2.7 mg albumin/mg
creatinine; n 5 4), and no cryoprecipitates have been noted
in any serum samples (10).
To see whether chronic intraperitoneal injections af-
fected Crry transgenic animals (which is relevant to ongo-
ing studies of chronic immune complex disease), seven trans-
genic animals were given daily intraperitoneal injections of
sterile PBS for 7 wk. Three of the seven animals were fed
25 mM ZnSO4 in drinking water for the duration of the
protocol. Glomeruli were then examined for immune
complexes. By IF microscopy for IgG, six of seven animals
had no detectable IgG, while the remaining animal had
trace IgG staining. All animals had detectable glomerular
IgM (average staining score 5 1.1 6 0.2), but this is no dif-
ferent than that found in normal mice (1.0 6 0.1; reference
10). Thus, there are no apparent phenotypic abnormalities
in adult mice related to continuous complement inhibition
by Crry.
Crry Transgenic Mice Are Protected from Ab-induced Glo-
merular Injury. Studies were then performed to evaluate
whether these animals were protected from glomerular in-
jury in NTS nephritis (Fig. 6). Crry transgenic mice (Tg 1
ve) were studied in parallel with littermates that were nega-
tive for the transgene (Tg 2 ve). A second group of Crry
transgenic animals was fed 25 mM ZnSO4 in drinking wa-
ter (Tg 1 ve Zn). NTS nephritis was induced in all animals
by intravenous injection of NTS IgG followed by an 18-h
urine collection. As shown in Fig. 6 A, there was a signifi-
cant reduction in urinary albumin excretion in Crry trans-
genic animals compared with transgene negative controls,
and this effect was more pronounced in animals fed zinc
(P , 0.05 by one-way analysis of variance with Tukey’s
multiple comparisons). The effect of sex was evaluated sta-
tistically, and individual data points are shown in Fig. 6 B
(males) and C (females). A distinct difference among sexes
was noted, with albuminuria of 7,195 6 1,344 and 1,941 6
415 mg/mg creatinine in transgene negative males (n 5 7)
and females (n 5 8), respectively. However, albuminuria was
reduced to a comparable extent in Crry transgenic animals
Figure 4. In situ RT-PCR on
renal tissue from Crry transgene
positive (A and B) and negative
(C) animals. The primers were
the same as used in Fig. 3.
Figure 5. Western blot analysis
showing the presence of intact rsCrry
in the urine of Crry transgenic animals.
Urine from Crry transgenic animals
was electrophoresed in lanes 2 and 4,
while purified rsCrry-Ig was in lanes 1
and 3 as a positive control. Western
blotting was performed with anti-
Crry mAb 10A2 (lanes 1 and 2), and
with anti-mouse CR1 mAb 8C12 as a
negative control (lanes 3 and 4). No
urinary Crry is detectable in nontrans-
genic mice (data not shown).1326 Protection from Ab-induced Injury in Transgenic Mice Overexpressing Crry
fed zinc (1,014 6 449 and 1,100 6 360 mg albumin/mg
creatinine in males and females, respectively; n 5 5 each).
Glomerular neutrophil counts 2 h after NTS IgG injec-
tion were 0.34 6 0.14 and 0.38 6 0.12 cells per glomerulus
in transgene positive and negative male mice, respectively.
At 18 h this mild neutrophil infiltration had completely
subsided, consistent with the transient nature of the neutro-
phil influx in this model (31). By IF microscopy, all animals
had intense linear staining for sheep IgG that was indistin-
guishable between the three groups (Fig. 7), suggesting that
the presence of rsCrry in the Crry transgenic mice did not
affect glomerular binding of the NTS IgG. C3 staining by
IF was significantly different between transgene negative
and positive animals (shown in graphical form for all ani-
mals in Fig. 8). No zinc-fed Crry transgenic animal had de-
tectable C3 staining in glomeruli, illustrating the effective-
ness of rsCrry to limit complement activation. Albuminuria
positively correlated with C3 staining in males (r 5 0.692,
P 5 0.002) and in females (r 5 0.605, P 5 0.008), support-
ing the conclusion that complement activation and C3
deposition were related to glomerular injury as measured
by albuminuria in this analysis.
Further studies examined the effect of Ab dose on NTS
nephritis disease manifestations. As occurred with the lower
dose of NTS IgG, Crry transgenic animals had significantly
less glomerular complement activation than transgene neg-
ative controls as assessed by IF microscopy (Table 1). How-
ever, Crry transgenic mice developed heavy albuminuria
that was comparable to transgene negative littermates.
Again consistent with the evanescent nature of the neutro-
phil influx, neutrophil accumulation at 18 h was unremark-
able, with ,0.3 cells/glomerulus in all groups. Thus, de-
spite the retained ability to inhibit complement activation
at the higher doses of injected Ab, Crry transgenic animals
developed albuminuria at these quantities of NTS IgG Ab.
Discussion
We have produced transgenic mice expressing rsCrry, a
potent inhibitor of complement C3 convertases (13, 21).
Whereas normal mice have endogenous Crry on cell mem-
branes (25), as well as circulating factor H and C4 binding
protein (35, 36), it was our goal to overexpress Crry as a
soluble protein to achieve chronic complement inhibition
to a substantially greater extent than that provided by these
intrinsic regulators. Several lines of evidence support our
conclusion that transgenic mice manifest the desired com-
plement inhibitory effect. First, we have shown in previous
studies that the form of rsCrry used here retains its inhibi-
tory activity (21), and that the addition of soluble forms of
Crry at comparable levels blocks complement activation in
normal mouse serum in the fluid phase and onto target sur-
faces (14, 21). Second, rsCrry isolated from the urine of
these Crry transgenic animals demonstrated the expected
complement inhibitory activity in vitro. Most importantly,
though, sera obtained from Crry transgenic animals were
less active in a classical pathway activation assay compared
with sera from transgene negative littermate controls, illus-
trating that transgene-derived rsCrry interfered with com-
plement activation.
In addition to having biologically significant levels of
rsCrry in sera, a secondary aim was to produce rsCrry in
tissue sites, such as the glomerulus, where it would exert an
effect on complement activation occurring locally. We
clearly show that such widespread tissue distribution was
achieved using the strategy we have chosen. Glomerular
expression of the Crry transgene derived mRNA was
readily apparent, and urinary levels of rsCrry relative to
Figure 6. Effects of complement inhibition on NTS IgG-induced al-
buminuria. NTS nephritis was induced in Crry transgenic mice (Tg 1 ve)
and in Crry transgenic animals in which the MT-I promoter was stimu-
lated with zinc feeding (Tg 1 ve Zn). Transgene negative littermate ani-
mals (Tg 2 ve) were studied in parallel. In A, the data are the mean 6
SEM of all animals, while in B and C individual data points are shown
from males (B) and females (C), with the average in each group depicted
as a horizontal line.1327 Quigg et al.
creatinine were sufficiently high to assure that this pool of
protein was primarily produced locally.
Despite the capacity of rodent glomerular cells to inhibit
complement activation using endogenous membrane-
anchored Crry and CD59 (25, 37, 38), in several Ab-
induced disorders complement activation occurs which ap-
parently overwhelms this intrinsic complement regulation
(15, 39–42). In the NTS nephritis model, NTS IgG first
binds to glomerular Ags, which is then followed by com-
plement activation (3, 15, 17). Here we show that glomer-
ular complement activation in NTS nephritis, as assessed by
glomerular C3 staining by IF, was significantly reduced in
Crry transgenic mice despite similar localization of IgG
anti-glomerular Abs. Furthermore, the most important ef-
fect of complement activation, which is the relative loss of
the glomerular barrier to protein passage manifested by the
development of albuminuria, was significantly diminished
in Crry transgenic animals. In our studies, males had greater
injury than females. It is known that the hemolytic activity
of male sera is higher than that from females, which is due
to a relative deficiency of C5, C6, and C7 in female mice
(43). This disparity in complement activity likely underlies
the differences we observed in these studies.
As has been shown previously, the complement depen-
dence of the NTS nephritis model becomes lost at higher
Ab doses (14, 16, 17). The mediator systems in NTS ne-
phritis have been dissected by Boyce and Holdsworth (17).
In their careful experiments, as the dose of NTS IgG was
raised, the disease first became neutrophil independent and
subsequently neutrophil and complement independent. In
our studies, NTS IgG doses of 1 mg and above led to ap-
parent complement- and neutrophil-independent glomeru-
lar damage. Such injury is believed to be due to direct reac-
tivity of NTS IgG with glomerular cell Ags (18). The
complement dependence of NTS nephritis has recently
been examined by Sheerin et al. (44) using mice made defi-
cient in C3 and C4. In these studies, injection of 0.5 mg of
NTS IgG led to albuminuria in wild-type mice, which was
reduced by 90 and 98% in C4- and C3-deficient mice, re-
spectively. Even with 1.0 mg NTS IgG, there was minimal
albuminuria in C3-deficient mice, and this was 13 times
less than wild-type mice. Despite this, neutrophil infiltra-
tion within 2 h of Ab injection was no different between
wild-type and C3-deficient animals, consistent with such a
dose leading to complement-dependent but neutrophil-
independent glomerular injury.
The effect of increasing rsCrry expression through stim-
ulation of the MT-I promoter with zinc feeding appeared
to have an additional effect on both C3 staining and albu-
minuria. However, since both of these outcome measures
were already significantly reduced in Crry transgenic ani-
mals not fed zinc, these differences did not reach statistical
significance between these two groups of Crry transgenic
animals. In these studies, we also could not separate out the
effects of systemic rsCrry from those of locally produced
rsCrry. To do so, either comparisons between Crry trans-
genic and normal mice given comparable amounts of
rsCrry systemically, or the generation of Crry transgenic
mice expressing rsCrry only outside of the target organ,
will be required.
In sum, this is the first biological example where long-
term complement inhibition has been achieved using trans-
genic techniques, and establishes the principle that chronic
therapy directed at the C3 activation step can be effective
in ameliorating disease. Proof of its utility will come from
studying a disorder such as the autologous NTS nephritis
model, in which injury is of a more chronic nature and
mediated by autologous IgG (29, 45). Given the current
Figure 7. IF staining for sheep IgG in representative glomeruli from mice given NTS IgG. Shown are glomeruli from transgene negative (A), trans-
gene positive (B), and zinc-fed transgene positive (C) animals.
Figure 8. Effects of complement inhibition on NTS-IgG induced C3
deposition in glomeruli. IF scoring intensity for C3 for individual animals
is shown, with the mean of each group as a horizontal line. The legends
are the same as in Fig. 6.1328 Protection from Ab-induced Injury in Transgenic Mice Overexpressing Crry
availability of functionally comparable human inhibitors
such as rsCR1 (46) and a decay-accelerating factor-mem-
brane cofactor protein chimera (47), our findings support
the potential utility of these compounds in patients with
Ab-mediated renal diseases, as well as those affecting other
organs.
Our results are also relevant to several other questions.
One potential problem with chronic complement inhibi-
tion is that the beneficial effects of complement to resist in-
fectious agents and to process naturally generated immune
complexes may be diminished. However, our accumulated
experience with .100 animals has shown that adult ani-
mals remain healthy in standard housing conditions, and
there is no apparent susceptibility to infections with envi-
ronmental pathogens. Furthermore, we have carefully studied
transgenic mice for the development of immune complex
disease of a similar nature as may occur with deficiencies of
individual complement components in humans (34) and
animals (48, 49), but have failed to identify such a predis-
position. We believe that two possible reasons account for
the lack of deleterious effects. The first is that we have not
completely inhibited complement activation, and sufficient
activity may remain to resist normal environmental patho-
gens and process immune complexes. Second, complement
components may be synthesized and directly secreted onto
pathogens by macrophages (50), and rsCrry may not signif-
icantly affect this process. Whatever the explanation,
though, we believe our results prove the principle that
chronic complement inhibition in adult animals is safe.
Our results are also relevant to current uncertainties re-
lated to the relative role of complement versus Fc receptors
(FcR) in initiating and amplifying acute and chronic in-
flammatory tissue damage in vivo. This issue has been stud-
ied by ourselves and others in several ways. Some results
have suggested that signals through FcR are the most im-
portant regulators of tissue injury (51–53), while others
have suggested that complement plays a central role (14,
54, 55). Certainly some of the differences in these results
are based on variations in the models studied, the target or-
gan, and/or the doses of disease-inducing reagents used.
Several studies have clearly demonstrated that the comple-
ment dependence of the tissue damage induced by lower
doses of disease-inducing Ab is lost when higher doses of
Ab are used (16, 17, 56). However, we believe that it is
also likely that FcR and complement activation fragments
each engage nonoverlapping inflammatory and immune
pathways. Recent studies of the effects of FcR g chain de-
ficiency on glomerulonephritis in the (NZB 3 NZW)F1
female model, in which glomerular C3 deposition is still
qualitatively present at similar levels and autoantibody lev-
els are unchanged, but there is less renal damage (53), are
consistent with this hypothesis. Relevant to this, a similar
decrease in renal disease was also reported using the same
model system in mice treated with inhibitory anti-C5 mAb
(5). The apparent lack of effect of FcR g chain deficiency
on humoral responses (57) as compared with the marked
decrease in C3-deficient (58) and C4/C3 receptor (Cr2)-
deficient mice (59, 60) also highlights the differences be-
tween inhibition of complement versus FcR. Indeed, if
there were inflammatory pathways differentially regulated
by each effector mechanism, blockade of both complement
activation and FcR effects at the same time should lead to
additive or synergistic effects. With our development of
these Crry transgenic mice and rsCrry-Ig as an exogenously
administered inhibitor (14) this hypothesis can now be ex-
perimentally tested.
Finally, previous studies in mice have shown that inhibi-
tion of complement activation at the generation of C5a
ameliorates arthritis in the CIA model (4) and glomerulo-
nephritis in (NZB 3 NZW)F1 female model of lupus (5).
However, it is possible that inhibition at the C3 activation
step would be more effective than C5 inhibitors. An inhib-
itor such as rsCrry (or rsCR1), because it decreases C3 acti-
vation and C3a liberation, may lead to decreased influx of
inflammatory cells that express the C3a receptor (61). Al-
ternatively, because C3 is required for a normal Ab re-
sponse to foreign Ag (58, 62, 63), pathogenic Ab genera-
tion may be decreased in the setting of a C3 convertase
inhibitor such as rsCrry. Each of these questions can now
be specifically addressed in relevant disease models by direct
comparison of the two strategies.
Table 1. Disease Variables in Mice Given Higher Doses of NTS IgG
1 mg 2 mg
Tg 1 ve Tg 2 ve Tg 1 ve Tg 2 ve
Albuminuria (mg/mg creatinine) 31,342 6 6,631 28,361 6 9,962 29,661 6 10,296 23,667 6 5,514
IF staining intensity for C3 0.3 6 0.2* 1.8 6 0.5* 0.3 6 0.2* 1.4 6 0.2*
Transgene positive and littermate negative mice were injected intravenously with 1 or 2 mg NTS IgG. Urine was collected for 18 h for albumin and
creatinine determinations, after which animals were killed and renal tissue was processed to determine glomerular C3 binding by IF microscopy.
Data represent the mean 6 SEM.
*P , 0.02 by ANOVA.1329 Quigg et al.
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